# AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor

Source: https://onco.cc/trials/nct07158840/  
OnCo record `nct07158840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab in lung cancer, run by Akeso, not yet recruiting.

## Summary

AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment is a phase 2, interventional study registered as NCT07158840 by Akeso, with a registry enrolment figure of 60 participants, started 2025-09-05 and due to reach its primary completion in 2028-09. Interventions recorded: AK112. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Overall response (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: AGA TKI NSCLC
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07158840
- Phase: 2
- Setting: A Single Arm, Multi-center, Phase II Study of AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
- Sponsor: Akeso
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07158840: https://clinicaltrials.gov/study/NCT07158840

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07158840.json